Silvestri, V., Barrowdale, D., Mulligan, A. M., Neuhausen, S. L., Fox, S., Karlan, B. Y., Mitchell, G., James, P., Thull, D. L., Zorn, K. K., Carter, N. J., Nathanson, K. L., Dornchek, S. M., Rebbeck, T. R., Ramus, S. J., Nussbaum, R. L., Olopade, O. I., Rantala, J., Yoon, S. Y., Caligo, M. A., Spugnesi, L., Bojesen, A., Pedersen, I. S., Thomassen, M., Jensen, U. B., Toland, A. E., Senter, L., Andrulis, I. L., Glendon, G., Hulick, P. J., Irnyanitov, E. N., Greene, M. H., Mai, P. L., Singer, C. F., Rappaport-Fuerhauser, C., Kramer, G., Vijai, J., Offit, K., Robson, M., Lincoln, A., Jacobs, L., Machackova, E., Foretova, L., Navratilova, M., Vasickova, P., Couch, F. J., Hallberg, E., Ruddy, K. J., Sharma, P., Kim, S. W., Teixeira, M. R., Pinte, P., Montagna, M., Matricardi, L., Arason, A., Johannsson, O. T., Barkardottir, R. B., Jakubowska, A., Lubinski, J., Izquierdo, A., Pujana, M. A., Balmana, J., Diez, O., Ivady, G., Papp, J., Olah, E., Kwong, A., Nevanlinna, H., Aittomaki, K., Segura, P. P., Caldes, T., Van Maerken, T., Poppe, B., Claes, K. B. M., Isaacs, C., Elan, C., Lasset, C., Stoppa-Lyonnet, D., Barjhoux, L., Belotti, M., Meindl, A., Gehrig, A., Sutter, C., Enger, C., Niederacher, D., Steinemann, D., Hahnen, E., Kast, K., Arnold, N., Varon-Mateeva, R., Wand, D., Godwin, A. K., Evans, D. G., Frost, D., Perkins, J., Adlard, J., Izatt, L., Platte, R., Eeles, R., Ellis, S., Hamann, U., Garber, J., Fostira, F., Fountzilas, G., Pasini, B., Giannini, G., Rizzolo, P., Russo, A., Cortesi, L., Papi, L., Varesco, L., Palli, D., Zanna, I., Savarese, A., Radice, P., Manoukian, S., Peissel, B., Barile, M., Bonanni, B., Viel, A., Pensotti, V., Tommasi, S., Peterlongo, P., Weitzel, J. N., Osorio, A., Benitez, J., McGuffog, L., Healey, S., Gerdes, A. M., Ejlertsen, B., Hansen, T. V. O., Steele, L., Ding, Y. C., Tung, N., Janavicius, R., Goldgar, D. E., Buys, S. S., Daly, M. B., Bane, A., Terry, M. B., John, E. M., Southey, M., Easton, D. F., Chenevix-Trench, G., Antoniou, A. C., Ottini, L., kConFab, Investigators, Hereditary Breast Ovarian Canc, Res, Embrace (2016) Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. BREAST CANCER RESEARCH, 18. ISSN 1465-5411

Preview

Text 14878.pdf Download (757kB) | Preview

Abstract

Background: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs). Methods: We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database. Results: Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 x 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 x 10(-12)). Conclusions: On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.

Item Type:	Article
Authors (ICR Faculty only):	Eeles, Ros
All Authors:	Silvestri, V., Barrowdale, D., Mulligan, A. M., Neuhausen, S. L., Fox, S., Karlan, B. Y., Mitchell, G., James, P., Thull, D. L., Zorn, K. K., Carter, N. J., Nathanson, K. L., Dornchek, S. M., Rebbeck, T. R., Ramus, S. J., Nussbaum, R. L., Olopade, O. I., Rantala, J., Yoon, S. Y., Caligo, M. A., Spugnesi, L., Bojesen, A., Pedersen, I. S., Thomassen, M., Jensen, U. B., Toland, A. E., Senter, L., Andrulis, I. L., Glendon, G., Hulick, P. J., Irnyanitov, E. N., Greene, M. H., Mai, P. L., Singer, C. F., Rappaport-Fuerhauser, C., Kramer, G., Vijai, J., Offit, K., Robson, M., Lincoln, A., Jacobs, L., Machackova, E., Foretova, L., Navratilova, M., Vasickova, P., Couch, F. J., Hallberg, E., Ruddy, K. J., Sharma, P., Kim, S. W., Teixeira, M. R., Pinte, P., Montagna, M., Matricardi, L., Arason, A., Johannsson, O. T., Barkardottir, R. B., Jakubowska, A., Lubinski, J., Izquierdo, A., Pujana, M. A., Balmana, J., Diez, O., Ivady, G., Papp, J., Olah, E., Kwong, A., Nevanlinna, H., Aittomaki, K., Segura, P. P., Caldes, T., Van Maerken, T., Poppe, B., Claes, K. B. M., Isaacs, C., Elan, C., Lasset, C., Stoppa-Lyonnet, D., Barjhoux, L., Belotti, M., Meindl, A., Gehrig, A., Sutter, C., Enger, C., Niederacher, D., Steinemann, D., Hahnen, E., Kast, K., Arnold, N., Varon-Mateeva, R., Wand, D., Godwin, A. K., Evans, D. G., Frost, D., Perkins, J., Adlard, J., Izatt, L., Platte, R., Eeles, R., Ellis, S., Hamann, U., Garber, J., Fostira, F., Fountzilas, G., Pasini, B., Giannini, G., Rizzolo, P., Russo, A., Cortesi, L., Papi, L., Varesco, L., Palli, D., Zanna, I., Savarese, A., Radice, P., Manoukian, S., Peissel, B., Barile, M., Bonanni, B., Viel, A., Pensotti, V., Tommasi, S., Peterlongo, P., Weitzel, J. N., Osorio, A., Benitez, J., McGuffog, L., Healey, S., Gerdes, A. M., Ejlertsen, B., Hansen, T. V. O., Steele, L., Ding, Y. C., Tung, N., Janavicius, R., Goldgar, D. E., Buys, S. S., Daly, M. B., Bane, A., Terry, M. B., John, E. M., Southey, M., Easton, D. F., Chenevix-Trench, G., Antoniou, A. C., Ottini, L., kConFab, Investigators, Hereditary Breast Ovarian Canc, Res, Embrace
Additional Information:	ISI Document Delivery No.: DD0DQ Times Cited: 0 Cited Reference Count: 30 Silvestri, Valentina Barrowdale, Daniel Mulligan, Anna Marie Neuhausen, Susan L. Fox, Stephen Karlan, Beth Y. Mitchell, Gillian James, Paul Thull, Darcy L. Zorn, Kristin K. Carter, Natalie J. Nathanson, Katherine L. Dornchek, Susan M. Rebbeck, Timothy R. Ramus, Susan J. Nussbaum, Robert L. Olopade, Olufunrnilayo I. Rantala, Johanna Yoon, Sook-Yee Caligo, Maria A. Spugnesi, Laura Bojesen, Anders Pedersen, Inge Sokilde Thomassen, Muds Jensen, Uffe Birk Toland, Amanda Ewart Senter, Leigha Andrulis, Irene L. Glendon, Gord Hulick, Peter J. Irnyanitov, Evgeny N. Greene, Mark H. Mai, Phuong L. Singer, Christian F. Rappaport-Fuerhauser, Christine Kramer, Gero Vijai, Joseph Offit, Kenneth Robson, Mark Lincoln, Anne Jacobs, Lauren Machackova, Eva Foretova, Lenka Navratilova, Marie Vasickova, Petra Couch, Fergus J. Hallberg, Emily Ruddy, Kathryn J. Sharma, Priyanka Kim, Sung-Won Teixeira, Manuel R. Pinte, Pedro Montagna, Marco Matricardi, Laura Arason, Adalgeir Johannsson, Oskar Th Barkardottir, Rosa B. Jakubowska, Anna Lubinski, Jan Izquierdo, Angel Angel Pujana, Miguel Balmana, Judith Diez, Orland Ivady, Gabriella Papp, Janos Olah, Edith Kwong, Ava Nevanlinna, Heli Aittomaki, Kristiina Perez Segura, Pedro Caldes, Trinidad Van Maerken, Tom Poppe, Bruce Claes, Kathleen B. M. Isaacs, Claudine Elan, Camille Lasset, Christine Stoppa-Lyonnet, Dominique Barjhoux, Laure Belotti, Muriel Meindl, Alfons Gehrig, Andrea Sutter, Christian Enger, Christoph Niederacher, Dieter Steinemann, Doris Hahnen, Eric Kast, Karin Arnold, Norbert Varon-Mateeva, Raymonda Wand, Dorothea Godwin, Andrew K. Evans, D. Gareth Frost, Debra Perkins, Jo Adlard, Julian Izatt, Louise Platte, Radka Eeles, Ros Ellis, Steve Hamann, Ute Garber, Judy Fostira, Florentia Fountzilas, George Pasini, Barbara Giannini, Giuseppe Rizzolo, Piera Russo, Antonio Cortesi, Laura Papi, Laura Varesco, Liliana Palli, Domenico Zanna, Ines Savarese, Antonella Radice, Paolo Manoukian, Siranoush Peissel, Bernard Barile, Monica Bonanni, Bernardo Viel, Alessandra Pensotti, Valeria Tommasi, Stefania Peterlongo, Paolo Weitzel, Jeffrey N. Osorio, Ana Benitez, Javier McGuffog, Lesley Healey, Sue Gerdes, Anne-Marie Ejlertsen, Bent Hansen, Thomas V. O. Steele, Linda Ding, Yuan Chun Tung, Nadine Janavicius, Ramunas Goldgar, David E. Buys, Saundra S. Daly, Mary B. Bane, Anita Terry, Mary Beth John, Esther M. Southey, Melissa Easton, Douglas F. Chenevix-Trench, Georgia Antoniou, Antonis C. Ottini, Laura National Cancer Institute [UM1 CA164920, RC4CA153828]; Research Council of Lithuania [LIG-07/2012]; Breast Cancer Research Foundation; Morris and Horowitz Families Endowed Professorship; NEYE Foundation; Spanish Association against Cancer [AECC08]; Mutua Madrilena Foundation (FMMA); RTICC [06/0020/1060]; Office of the Director, National Institutes of Health; Fondazione IRCCS Istituto Nazionale Tumori; FiorGen Foundation for Pharmacogenomics; AIRC [IG12780]; FIRC; Cancer Research UK [C1287/A10118, C1287/A11990, C5047/A8385, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565]; NHMRC; European Union [European Social Fund (ESF)]; Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF)-Research Funding Program of the General Secretariat for Research & Technology: ARISTEIA; European Social Fund; DKFZ. EMBRACE; NIHR grant to the Biomedical Research Centre, Manchester, UK; Royal Marsden NHS Foundation Trust; NIHR; Biomedical Research Centre; University of Kansas Cancer Center [P30 CA168524]; Kansas Bioscience Authority Eminent Scholar Program; Chancellors Distinguished Chair in Biomedical Sciences Professorship; German Cancer Aid [110837]; Center for Molecular Medicine Cologne (CMMC); Ligue Nationale Contre le Cancer; Association "Le cancer du sein, parlors-enl" Award; Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer; National Institute of Cancer (INCa); Non-Therapeutic Subject Registry Shared Resource at Georgetown University (NIH/NCI) [P30-CA051008]; Fisher Center for Familial Cancer Research; GOA [BOF10/GOA/019]; ISCIII (Spain) [RD12/00369/0006, 12/00539]; European Regional Development FEDER funds; Helsinki University Hospital Research Fund, Academy of Finland [266528]; Finnish Cancer Society and the Sigrid Juselius Foundation; Dutch Cancel Society [NKI1998-1854, NKI2004-3088, NKI2007-3756]; Netherlands Organization of Scientific Research [NWO 91109024]; Pink Ribbon [110005, 2014-187.WO76]; BBMRI [NWO 184.021.007/CP46]; Dutch Cancer Society [NKI1998-1854, NKI2004-3088, NKI2007-3756]; Transcan [JTC 2012]; Cancer [12-054]; Hong Kong Hereditary Breast Cancer Family Registry; Dr. Ellen Li Charitable Foundation, Hong Kong; Hungarian research [KTA-OTKA CK-80745, OTPA K-112228]; Norwegian EEA Financial Mechanism [Hu0115/NA/2008-3/OP-9]; Asociacion Espanola Contra el Cancer, Spanish Health Research Fund; Carlos III Health Institute; Catalan Health Institute and Autonomous Government of Catalonia; ISCIIRETIC [RD06/0020/1051, RD12/0036/008, PI10/01422, PI10/00748, PI13/00285, PIE13/00022, 2009SGR290, 2014SGR364]; IHCC [PBZ_KBN_122/P05/2004]; Icelandic Association "Walking for Breast Cancer Research"; Landspitali University Hospital Research Fund; Liga Portuguesa Contra o Cancro; National Breast Cancer Foundation, and previously; National Health and Medical Research Council (NHMRC); Queensland Cancer Fund; Cancer Councils of New South Wales, Victoria, Tasmania and South Australia; Cancer Foundation of Western Australia; National Breast Cancer Foundation, Cancer Australia; National Institutes of Health (USA); National R&D Program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea [1020350]; NIH, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116167, CA128978, CA176785, CA116201]; U.S. Department of Defense Ovarian Cancer Idea award [W81XWH-10-1-0341]; David F. and Margaret rein Family Foundation; Ting Tsung and We Fong Chao Foundation; MH CZ - DRO [MMCI, 00209805]; European Regional Development Fund; State Budget of the Czech Republic [RECAMO,CZ.1.05./21.00/03.0101]; Charles University in Prague [UNCE204024]; Robert. and Kate Niehaus Clinical Cancer Genetics Initiative; Andrew Sabin Reserch Fund; Intramural Research Program of the National Cancer Institute, [711]; Russian Federation for Basic Research [13-04-92613, 14-04-93959, 15-04-01744]; Ohio State University Comprehensive Cancer Center; ITT (Istituto Toscano Tumori); SEABASS: Ministry of Science, Technology and Innovation Ministry of Higher Education and Cancer Research Initiatives Foundation [UMC/HIR/MOHE/06]; Malaysia Ministry of Science, Technology and Innovation, Ministry of Higher Education [UM.C/HIR/MOHE/06]; Cancer Research Initiatives Foundation; Swedish, Cancer Society; NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA125183, R01 CA142996, 1U01CA161032]; Ralph and Marion Falk Medical Research Trust; Entertainment Industry Fund National Womens Can Research Alliance and the Breast Cancer research Foundation; CRUK; University Pennsylvania National Instiutes of Health (NIH) [R01-CA102776, R01-CA083855]; Susan G. Komen Foundation forte Cure, Basser Research Center; UPITT/MWH: Frieda G. and Saul F. Shapira BRCA-Associated Cancer Research Program; VFCTG: Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation Geoffrey Lindeman, Marion Harris, Martin Delatyki of the Victorian Familial Cancer Trials Group; American Cancer Society Early Detection Professorship [SIOP-06-258-01-COUN]; National Center for Advancing Translational Sciences (NCATS) [UL1TR000124]; European Community's Seventh Framework Programme [223175, HEALTH-F2-2009-223175]; National Institutes of Health [CA128978]; Post-Cancer GWAS initiative [1U19 CA148537, 1U19 CA148065, 1U19 CA146112]; U.S. Department of Defense [W81XWH-10-1-0341]; Canadian Institutes of Health Research (CIHR); CIHR Team in Familial Risks of Breast Cancer, Komen Foundation; Ovarian Cancer Research Fund; [SAF2010-20493]; [FISPI08/1120]; [5U01CA113916]; [R01CA140323]; [NO2-CP-11019-50]; [N02-CP-65504] BCFR: This work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government or the BCFR. BCFR-AU: Acknowledge Maggie Angelakos, Judi Maskiell, Gillian Dite and Helen Tsimiklis. BCFR-NY: We thank members and participants in the New York site of the Breast Cancer Family Registry for their contributions to the study. BCFR-ON: We thank members and participants in the Ontario Familial Breast Cancer Registry for their contributions to the study. BFBOCC-LT is partly supported by Research Council of Lithuania grant LIG-07/2012. We acknowledge Vilius Rudaitis and Laimonas Griskevicius. BIDMC is supported by the Breast Cancer Research Foundation. BRICOH: SLN was partially supported by the Morris and Horowitz Families Endowed Professorship. CBCS: This work was supported by the NEYE Foundation. CNIO: This work was partially supported by Spanish Association against Cancer (AECC08), RTICC 06/0020/1060, FISPI08/1120, Mutua Madrilena Foundation (FMMA) and SAF2010-20493. We thank Alicia Barroso, Rosario Alonso and Guillermo Pita for their assistance. COH-CCGCRN: City of Hope Clinical Cancer Genetics Community Network and the Hereditary Cancer Research Registry, supported in part by award number RC4CA153828 (JNW, principal investigator) from the National Cancer Institute and the Office of the Director, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. CONSIT TEAM: Funds from Italian citizens who allocated the 5 x 1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT institutional strategic projects '5 x 1000') to SM and from FiorGen Foundation for Pharmacogenomics to LP. LO is supported by AIRC (IG12780). VS is supported by FIRC (triennial fellowship "Mario e Valeria Rindi"). We acknowledge Maria Grazia Tibiletti of the Ospedale di Circolo-Universita dell'Insubria, Varese, Italy. CORE: The CIMBA data management and data analysis were supported by Cancer Research UK grants C12292/A11174 and C1287/A10118. SH is supported by an NHMRC program grant (to GCT). ACA is a Cancer Research UK senior cancer research fellow. GCT is an NHMRC senior principal research fellow. DEMOKRITOS: This research has been co-financed by the European Union [European Social Fund (ESF)] and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF)-Research Funding Program of the General Secretariat for Research & Technology: ARISTEIA. Investing in knowledge society through the European Social Fund. DKFZ: The DKFZ study was supported by the DKFZ. EMBRACE is supported by Cancer Research UK grants C1287/A10118 and C1287/A11990. DGE and Fiona Lalloo are supported by an NIHR grant to the Biomedical Research Centre, Manchester, UK. The investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE and Elizabeth Bancroft are supported by Cancer Research UK grant C5047/A8385.; RE is also supported by NIHR support of the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIHR support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. FCCC: The authors acknowledge support from The University of Kansas Cancer Center (P30 CA168524) and the Kansas Bioscience Authority Eminent Scholar Program. AKG was funded by 5U01CA113916, R01CA140323, and by the Chancellors Distinguished Chair in Biomedical Sciences Professorship. We thank Ms. Jo Ellen Weaver and Dr. Betsy Bove for their technical support. GC-HBOC: The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant 110837 to Rita K. Schmutgler) and by the Center for Molecular Medicine Cologne (CMMC). GEMo: The study was supported by the Ligue Nationale Contre le Cancer; the Association "Le cancer du sein, parlors-enl" Award; the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer program and the trench National Institute of Cancer (INCa). Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO) study: National Cancer Genetics Network "UNICANCER Genetic Group", France. We thank all the GEMO collaborating groups for their contribution to this study. DEMO Collaborating Centers are Coordinating Centres: Unite Mixte de Genetique Constitutionnelle des Cancers Frequents, Hospices Gyms de Lyon - Centre Leon Berard, & Equipe Genetique du cancer du sein", Centre de Recherche en Cancerologie de Lyon: Olga Sinilnikova dagger, Sylvie Nlazoyer, Francesca Damiola, Laure Barjhoux, Carole Verny-Pierre, Melanie Leone, Nadia Boutry-Kryza, Alain Calender, Sophie Grand; and Service de Genetique Oncologique, Institut Curie, Paris: Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Claude Houdayer, Etienne Rouleau, Lisa Golmard, Agnes Collet Virginie Moncoutier, Cedrick Lefol, Muriel Belotti, Antoine de Pauw, Camille Elan, Catherine Nogues, Emmanuelle Fourme Anne-Marie Birot. Institut Gustave Roussy,Villejuif Brigitte Bressac-de-Paillerets, Olivier Caron, Marine Guillaud-Batasille Centre Jean Perrin, Clerrnont-Ferrand: Yves-Jean Bignon, Nancy Uhrhammer. centre Leon Berard, Lyon: Christine Lasset, Valerie Bonadona, Sandrine Handallou. Centre Francois Baclesse, Caen: Agnes Hardouin, Pascaline Berthet, Dominique Vaur, Laurent Castera. Institut Paoli Calmettes, Marseille: Hagay Sobol, Violaine Bourdon, Tetsuro Noguchi Audrey Remenieras, Francois Eisinger. CHU Arnaud-de-Villeneuve, Montpellier: Isabelle Coupier, Pascal Pujol. Centre Oscar Lambret, Lille: Jean-Philippe Peyrat, Joelle Fournier, Francoise Revillion PhilippeVennint dagger, Claude Adenis. Centre Paul Strauss, Strasbourg: Daniele Muller, Jean-Pierre Fricker. Institut Bergonie, Bordeaux: Emmanuelle Barouk-Simonet, Francoisc Bonn I, Bubien, Nicolas Sevenet, Michel Longy. Institut Claudius Regaud, Toulousee: Christine Tor la Rosine Guimbaud, Laurence Gladieff, Viviane Feillel. CHU Grenoble: Dominique Leroux Helene Dreyfus, Christine Rebischung, Magalie Peysselon. CHU Dijon: Fanny Coron, Laurence Faivre. CHU St-Etienne: Fabienne Prieur, Marine Lebrun, Caroline Kientz. Hotel Dieu Centre Hospitalier, Chambery: Sandra Fert Ferrer. Centre Antoine Lacassagne, Nice: Marc Frenay CHU Limoges: Laurence Venat-Bouvet. CHU Nantes: Capucine Delnatte. CHU Bretonncau, Tours: Isabelle Mortemonsque.; Groupe Hospitalier Pitie-Salpetriere, Pals: Florence Coulet, Chrystelle Cobs, Florent Soubrier, Mathilde Warcoin. CHU Vandoeuvre-les-Nancy Johanna Sokolowska, Myriam Bronner CHU Besancon: Marie-Agnes Collonge-Rame, Alexandre Damette. Creighton University, On NE, USA Henry T. Lynch, Carrie L. Snyder. Georgetown University: CI received support from the Non-Therapeutic Subject Registry Shared Resource at Georgetown University (NIH/NCI grant P30-CA051008), the Fisher Center for Familial Cancer Research, and Swing for the Cure. G-FAST: Kim De Leeneer is supported by GOA glaint BOF10/GOA/019 (Ghent University) and spearhead financing of Ghent University Hospital. We thank the technical support of IIse Coene en Brecht Crombez. was supported by a grant RD12/00369/0006 and 12/00539 from ISCIII (Spain), partially supported by European Regional Development FEDER funds. We acknowledge Alicia Tosar for her technical assistance. HEBCS was financially supported by the Helsinki University Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society and the Sigrid Juselius Foundation. HEBCS thanks Taru A. Mu amen, Drs. Carl Blomqvist and Kirsimari Aaltonen and RNs Irja Erkkila and Virpi Palola for their help with the HEBCS data and samples. HERON is supported by the Dutch Cancel Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the Netherlands Organization of Scientific Research grant NWO 91109024, the Pink Ribbon grant 110005 and the BBMRI grant NWO 184.021.007/CP46. HEBON thanks the registration teams of the Comprehensive Cancer Centre Netherlands and Comprehensive Centre South (together the Netherlands Cancer Registry) and PALGA (Dutch Pathology Registry) for part of the data collection. The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HERON) consists of the following collaborating centres: coordinating centre: Netherlands Cancer Institute, Amsterdam, the Netherlands: M. A. Rookus, F. B. L. Hogervorst F. E. van Leeuwen, S. Verhoef, M. K Schmidt, N. S. Russell, J. L. de Lange, R. Wijnands; Erasmus Medical Center, Rotterdam, the Netherlands:1 M. Collee A. M. W. van den Ouweland, M. J. Floc ning, C. Seynaeve, C. H. M. van Deurzen, I. M. Obdeijn; Leiden University Medical Center, the Netherlands: C. J. van Asperen, J. T. Wijnen, R. A. E. M. Tollenaar, P. Devilee, T. C T. E. F. van Cronenburg; Radboud University Nijmegen Medical Center, the Netherlands: C. M. Kets, A. R. Mensenkamp; University Medical Center Utrecht, the Netherlands: M. G. E. M. Ausems, R. B. van der Luijt, C. C. van der Pol; Amsterdam Medical Center, Amsterdam, the Netherlands: C. M. Aalfs, T. A. M. van Os; VU University Medical Center, Amsterdam, Amsterdam, the Netherlands: j. J. P. Gille, Q. Waisfisz, H University Hospital Maastricht, the Netherlands: E. B. Gomez-Garcia M. J Blok; University Medical Center (Groningen, the Netherlands: J.C Oosterwijk, A. H. van der Hout, M. J. Mourits, G. H. de Bock; -File Netherlands Foundation for the detection of hereditary tumours, Leiden, the Netherlands: H. F. Vasen; The Netherlands Comprehensive Cancer Organization (IKNL): S. Siesling, J. Verloop; The Dutch Pathology Registy (PALGA): L. I. H. Overbeek. The HEBON study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088 NKI2007-3756, the Netherlands Organization of Scientific Research grant NWO 91109024, the Pink Ribbon grants 110005 and 2014-187.WO76, the BBMRI grant NWO 184.021.007/CP46 and the Transcan grant JTC 2012 Cancer 12-054. HEBON thanks the registration teams of IKNL. and PALGA for part of the data collection.; HRBCP is supported by The Hong Kong Hereditary Breast Cancer Family Registry and the Dr. Ellen Li Charitable Foundation, Hong Kong. We, the thank Hong Kong Sanatorium and Hospital for their continual support HUNBOCS: Hungarian Breast and Ovarian Cancer Study was supported by Hungarian research grants KTA-OTKA CK-80745, OTPA K-112228 and the Norwegian EEA Financial Mechanism Hu0115/NA/2008-3/OP-9. We thank the ilungarian Breast and Ovarian Cancer Study Group members Gangs Papp, Tibor Vaszko Aniko Bozsik, Timea Pocza, Judit Franko, Maria Balogh, Gabriella Domokos, Judit Ferenczi, Department of Molecular Genetics, National Institute of Oncology, Budapest Hungary) and the clinicians and patients for their contributions to this study. HVH: We, thank the Oncogcnetics Group (VHIO), and the High Risk and Cancer Prevention Unit of the University Hospital Vall d'Hebron. ICO: Contract grant sponsor: Asociacion Espanola Contra el Cancer, Spanish Health Research Fund; Carlos III Health Institute; Catalan Health Institute and Autonomous Government of Catalonia. contract grant numbers: ISCIIRETIC RD06/0020/1051, RD12/0036/008 PI10/01422, PI10/00748, PI13/00285, PIE13/00022, 2009SGR290 and 2014SGR364. We thank the ICO Hereditary Cancer Program team led by Dr. Gabriel Capella. The IHCC was supported by Grant PBZ_KBN_122/P05/2004. The ILUH group was supported by the Icelandic Association "Walking for Breast Cancer Research" and by the Landspitali University Hospital Research Fund. IOVHBOCS is supported by Minister() della Salute and "5x1000" Istituto Oncologico Veneto grant. IPOBCS: This study was part supported by Liga Portuguesa Contra o Cancro. We thank Drs. Ana Peixoto, Catarina Santos, Patricia Rocha and Pedro Pinto for their skilful contribution to the study. kConFab is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia; We, thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and. staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study [which has received funding from the NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the National Institutes of Health (USA)] for their contributions to this resource, and the many familles who contribute to kConFab. KOIIBRA is supported by a grant from the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea (1020350). MAYO is supported by NIH grants CA116167, CA128978 and CA176785, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341), a grant from the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret rein Family Foundation and the Ting Tsung and We Fong Chao Foundation. MODSQUAD was supported by MH CZ - DRO (MMCI, 00209805) and by the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO,CZ.1.05./21.00/03.0101) to LF, and by Charles University in Prague project UNCE204024 (to MZ).; MODSQUAD acknowledges ModSQuaD members Csilla Szabo (National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA) and Michal Zikan, Petr Pohlreich and Zdenek Kleibl (Oncogynecologic Center and Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic). MSKCC is supported by grants from the Breast Cancer Research Foundation, the Robert. and Kate Niehaus Clinical Cancer Genetics Initiative, and the Andrew Sabin Reserch Fund. NCI: The research of MHG and PLM was supported by the Intramural Research Program of the National Cancer Institute, 711, and by support services contracts NO2-CP-11019-50 and N02-CP-65504 with Westat, Inc., Rockville, MD, USA. NNPIO: This work has been supported by the Russian Federation for Basic Research (grants 13-04-92613, 14-04-93959 and 15-04-01744). OCGN: We thank members and participants in the Ontario Cancer Genetics Network for their contributions to the study. OSUCCG is supported by The Ohio State University Comprehensive Cancer Center. Leigha Senter, Kevin Sweet, Caroline Craven and Michelle O'Conor were in in accrual of study participants, ascertainment of medical records and database management. Samples were processed by the OSU Human Genetics Sample Bank. PBCS: This work was supported by the ITT (Istituto Toscano Tumori) grants 2011-2013. SEABASS: Ministry of Science, Technology and Innovation Ministry of Higher Education (UMC/HIR/MOHE/06) and Cancer Research Initiatives Foundation. We thank Yip Cheng Har, Nur Aishah Mohd Talb, Phuah Sze Yee, Norhashimah Hassan and all the research nurses, research assistants and doctors involved in the MyBrCa Study for assistance in patient recruitment, data collet on and sample preparation. In addition, we thank Philip lau, Sng Jen-Hwei and Sharifah Nor Akmal for contributing samples from the Singapore Breast Cancer Study and the HUKM-HKL Study, respectively. The Malaysian Breast Cancer Genetic Study is funded by resarch grants from the Malaysia Ministry of Science, Technology and Innovation, Ministry of Higher Education (UM.C/HIR/MOHE/06) and charitable funding from Cancer Research Initiatives Foundation. SWE-BRCA collaborators are supported by the Swedish, Cancer Society. Swedish, scientists participating as SWE-BRCA collaborators are as follows: from Lund University and University Hospital: angstrom ke Borg, Hakan Olsson, Helena Jemstrom, Karin Henriksson, Katja Harbst, Maria Soller, Ulf Kristoffersson; from Gothenburg Sahlgrenska University Hospital: Anna Ofverholm, Margareta Nordling, Per Karlsson, Zakaria Einbeigi; from Stockholm and Karolinska University Hospital: Anna von Wachenfeldt, Annelle Liljegren, Annika Lindblom, Brita Arver, Gisela Barbany Bustinza, Johanna Rantala; from Umea University Hospital: Beatrice Melin, Christina Edwinsdotter Ardnor, Monica Emanuelsson; from Uppsala University: Hans Ehrencrona, Maritta Hellstrom Pigg, Richard Rosenquist; from Linkoping University Hospital: Marie Stenmark-Askmalm, Sigrun Liedgren. The University of Chicago is supported by NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA125183), R01 CA142996, 1U01CA161032 and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund National Womens Can Research Alliance and the Breast Cancer research Foundation. OIO is an American Cancer Society clinical research professor.; We thank Cecilla Zvocec, Qun Niu, physicians, genetic counsellors, research nurses anti staff of the Cancer Risk Clinic for their contributions to this resource, and the many families who contribute to Our program. UCSF Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center. We thank the following genetic counsellors for participant recruitment: Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart Robin Lee, Amie Blanco and Peggy Conrad. Thanks are also extended to Ms. Salina Chan for her data management. UKFOCR was supported by a project grant from CRUK to Paul Pharoah. We thank Paul Pharoah, Simon Gayther Susan Ramus, Carole Pye, Patricia Harrington and Eva Wozniak for their contributions to the UKFOCR. University Pennsylvania National Instiutes of Health (NIH) (grants R01-CA102776 and R01-CA083855); Breast Cancer Research Foundation; Susan G. Komen Foundation forte Cure, Basser Research Center for BRCA. UPITT/MWH: Frieda G. and Saul F. Shapira BRCA-Associated Cancer Research Program; Hackers for Hope Pittsburgh. VFCTG: Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation Geoffrey Lindeman, Marion Harris, Martin Delatyki of the Victorian Familial Cancer Trials Group.;Ale thank Sarah Sawyer and Rebecca Driessen for assembling this data and Ella Thompson for performing all DNA amplification. WCP: BYK is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and National Center for Advancing Translational Sciences (NCATS) grant UL1TR000124. Funding for the ICOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement number 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA146112 - the GAME-ON Initiative), the U.S. Department of Defense (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation and the Ovarian Cancer Research Fund. 0 Biomed central ltd London 1465-5411
Uncontrolled Keywords:	Male breast cancer BRCA1/2 Pathology Histologic grade Genotype-phenotype correlations population risk carcinoma features grade Oncology
Research teams:	ICR divisions > Genetics and Epidemiology > Oncogenetics ICR divisions > Radiotherapy and Imaging > Oncogenetics
Depositing User:	Franziska Noessig
Date Deposited:	14 Mar 2016 16:45
Last Modified:	17 Mar 2016 15:59
URI:	http://publications.icr.ac.uk/id/eprint/14878

Actions (login required)

View Item